Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

University of Ottawa

$100,000.00

Improving myoblast transplantation outcomes via pharmacological reprogramming: stimulation of C/EBPbeta expression maintains stem cell identity

EF 2016-17

Résumé
One way to cure Duchenne muscular dystrophy (DMD) is to use stem cells to repair muscle. These stem cells, called satellite cells, can restore dystrophin expression to DMD muscle, reversing the muscle mass loss and weakness. However, when we isolate healthy satellite cells from muscle for transplant, they change in the dish, making them less efficient at repairing muscle when transplanted and less likely to make new satellite cells in the diseased muscle. New satellite cells from donor tissue are necessary for long-term repair of DMD muscle. My lab has discovered that a protein called C/EBPbeta helps satellite cells keep their stem cell potential. Treatment of donor myoblasts with a drug called IBMX before transplantation increases C/EBPbeta levels and makes the cells more like satellite cells, essentially reprogramming them into more potent stem cells. When transplanted into dystrophic muscle, IBMX-treated muscle cells repair better and make new muscle stem cells in mice. We now want to know if the IBMX-treated cells persist long term and make muscle function better, if we can further improve our protocol by preventing C/EBPbeta breakdown, and whether IBMX can also improve human muscle cells for transplant. Our preliminary data indicates that IBMX can stimulate C/EBPbeta in human muscle cells and reprogram them into a more stem-cell-like state, making it important to follow up our findings with strong pre-clinical data.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
351810
Name
Wiper-Bergeron Nadine L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Improving myoblast transplantation outcomes via pharmacological reprogramming: stimulation of C/EBPbeta expression maintains stem cell identity
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Ccaat/Enhancer Binding Protein Beta; Cell-Based Therapy; Duchenne Muscular Dystrophy; Myoblast; Nutlin-3a; Phosphodiesterase Inhibitor; Satellite Cell; Transplantation
Abstract
One way to cure Duchenne muscular dystrophy (DMD) is to use stem cells to repair muscle. These stem cells, called satellite cells, can restore dystrophin expression to DMD muscle, reversing the muscle mass loss and weakness. However, when we isolate healthy satellite cells from muscle for transplant, they change in the dish, making them less efficient at repairing muscle when transplanted and less likely to make new satellite cells in the diseased muscle. New satellite cells from donor tissue are necessary for long-term repair of DMD muscle. My lab has discovered that a protein called C/EBPbeta helps satellite cells keep their stem cell potential. Treatment of donor myoblasts with a drug called IBMX before transplantation increases C/EBPbeta levels and makes the cells more like satellite cells, essentially reprogramming them into more potent stem cells. When transplanted into dystrophic muscle, IBMX-treated muscle cells repair better and make new muscle stem cells in mice. We now want to know if the IBMX-treated cells persist long term and make muscle function better, if we can further improve our protocol by preventing C/EBPbeta breakdown, and whether IBMX can also improve human muscle cells for transplant. Our preliminary data indicates that IBMX can stimulate C/EBPbeta in human muscle cells and reprogram them into a more stem-cell-like state, making it important to follow up our findings with strong pre-clinical data.
Competitiondate
201604
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wiper-Bergeron, Nadine L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~